Cancer Biomarkers

Protein Biomarkers can be used as biomarkers for early detection of cancers especially used for the identification of breast cancer. Diagnostic Patients with suspected pancreatic cancer will undergo an initial CT scan to determine if a suspect mass is localized and removed by surgery 63% of patients will be diagnosed with non-resectable stage III and IV disease and a biopsy will be undertaken to confirm pancreatic cancer by H&E pathological analysis.  The presence of cancerous cells via pathology is very challenging due to high numbers of non-cancerous stromal infiltrating cells and administration of chemotherapy or enrolment into a clinical trial will only commence on definitive diagnosis of pancreatic cancer. These will notice specifically stains neoplastic pancreatic cells would enable the pathologist to confidently diagnose pancreatic cancer and thus offer appropriate cancer treatment to the patients. The Novel Biomarker BI-010 has been identified as a highly sensitive (98%) and specific (95%) IHC marker for pancreatic cancer and CRT is seeking a partner to develop an IHC based test to detect BI-010 in fine needle aspirate biopsies from biopsy samples.

  • Biomarkers in cancer research
  • Biomarkers in medicine
  • Risk assessment, diagnosis
  • Prognosis and treatment predictions
  • Molecular cancer biomarkers

Related Conference of Cancer Biomarkers

June 10-11, 2024

8th Global Meeting on Oncology and Radiology

Barcelona, Spain
July 11-12, 2024

24th World Congress on Cancer and Diagnostics

Vancouver, Canada
July 18-19, 2024

14th World Congress on Breast Cancer

Paris, France
September 16-17, 2024

9th World Conference on Breast and Cervical Cancer

London, UK
September 19-20, 2024

25th World Congress on Cancer Summit

Paris, France
November 24-25, 2024

7th International Conference on Anti-Cancer Drugs

Vancouver, Canada

Cancer Biomarkers Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in